What is BPC-157 and where does it come from?

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide — a fifteen-amino-acid sequence — derived from a protein naturally found in human gastric juice. It was identified and isolated during research into endogenous gastric peptides with cytoprotective properties. BPC-157 is not found in food and is not a naturally occurring circulating peptide; it is synthesized as a research compound. It is not FDA-approved and is currently under review for its 503A compounding classification ahead of the July 2026 FDA PCAC meeting.

What tissue repair properties has BPC-157 demonstrated in preclinical research?

Preclinical research has documented BPC-157 activity across multiple tissue-repair mechanisms: it promotes angiogenesis (new blood vessel formation) by upregulating VEGF and stimulating endothelial cell migration; it activates fibroblast proliferation and collagen synthesis relevant to tendon and musculoskeletal repair; it modulates nitric oxide (NO) signaling to reduce inflammation; and it exhibits gastrointestinal cytoprotection in rodent models of mucosal injury. These effects have been observed across a range of animal models, including studies of tendon rupture, bone fracture, GI fistula, and neurological injury. Human clinical data remains limited to small pilot cohorts.

Is BPC-157 legal to research in the United States?

BPC-157 is not an FDA-approved drug and is not scheduled as a controlled substance. It has historically been available for researcher and patient-specific use through 503A compounding pharmacies. Its current 503A classification is Category 2 — a regulatory holding position indicating prior PCAC review found insufficient evidence for positive listing, but no final prohibition has been issued. The July 2026 FDA PCAC meeting will re-evaluate this classification. Researchers sourcing BPC-157 through licensed 503A compounders are operating within the current regulatory framework, though that framework is under active review.

What Is BPC-157? A Research Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of a protein found in human gastric juice. It is one of the most extensively studied peptides in preclinical regenerative biology, with the majority of published literature examining tissue repair, gastrointestinal protection, and nervous system effects in rodent models. All information presented here is drawn from peer-reviewed preclinical and in vitro literature. This content is intended for research purposes only and does not constitute medical advice or guidance for human use.

Molecular Identity and Origin

BPC-157's amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a partial fragment of the larger gastric juice protein BPC, first characterized by Predrag Sikiric and colleagues at the University of Zagreb. Because this 15-residue sequence does not occur freely in nature in its isolated form, BPC-157 is classified as a synthetic research compound rather than a naturally occurring peptide.

The compound is notable for its relative stability in aqueous and acidic solution compared to many peptides, a property that has facilitated its use in both oral and parenteral rodent administration models. The free base and acetate salt forms are chemically distinct, a distinction that the FDA has treated as relevant for regulatory purposes (see Regulatory Status section below).

Molecular weight: 1,419.5 Da
Sequence length: 15 amino acids
CAS registry: 137525-51-0 (free base)

See the BPC-157 compound library entry for molecular data, sequence, and registry identifiers.

Proposed Mechanisms of Action

EGR-1 Transcription Factor Modulation

One of the central mechanistic hypotheses in BPC-157 research involves modulation of Early Growth Response Protein 1 (EGR-1), a zinc-finger transcription factor that regulates genes involved in tissue repair, angiogenesis, and cell proliferation. Sikiric et al. (2018, Current Pharmaceutical Design) proposed that BPC-157's cytoprotective effects may be partially mediated through EGR-1 upregulation, which in turn drives expression of downstream repair effectors including VEGF, FGF, and extracellular matrix remodeling enzymes.

Direct mechanistic evidence — from chromatin immunoprecipitation or promoter-reporter assays in human cell lines — remains limited. Most mechanistic data derives from rodent in vivo models and immortalized cell culture systems.

Nitric Oxide System Interactions

Multiple publications from the Sikiric laboratory have described cross-talk between BPC-157 and the nitric oxide (NO) system. Studies using the NOS inhibitor L-NAME and the NOS substrate L-arginine in rodent models indicated that BPC-157's gastrointestinal protective effects could be partially attenuated or amplified by pharmacological manipulation of NOS activity, implicating endothelial NO synthase (eNOS) in its cytoprotective profile (Sikiric et al., Life Sciences, 2001). The molecular interaction sites between BPC-157 and NO synthase isoforms have not been fully defined.

VEGF-Mediated Pro-Angiogenic Activity

A notable body of work has examined BPC-157's apparent ability to stimulate vascular endothelial growth factor (VEGF) expression. Chang et al. (2014, Journal of Applied Physiology) reported increased VEGF mRNA and protein expression in tendon fibroblast cultures treated with BPC-157, with associated increases in HUVEC tubule formation in co-culture assays. Hsieh et al. (2015, Phytomedicine) reported accelerated wound closure and increased microvessel density in rat skin injury models, findings consistent with a pro-angiogenic activity profile. These results are from animal and cell-culture models.

Dopaminergic and Serotonergic Pathway Interactions

The Sikiric group has also published extensively on BPC-157's interactions with monoamine neurotransmitter systems. In rodent behavioral models, BPC-157 administration appeared to attenuate dopaminergic overstimulation and modulate serotonin receptor activity in gut-brain axis contexts (Sikiric et al., Current Neuropharmacology, 2018). These observations have been proposed to underlie both the gastrointestinal and some of the CNS behavioral effects observed in rodent pharmacology studies.

Tissue Repair: Preclinical Data by Tissue Type

Tendon and Ligament

The most replicated category of BPC-157 preclinical research involves musculoskeletal healing models. Staresinic et al. (2003, Journal of Orthopaedic Research) demonstrated significantly accelerated Achilles tendon healing in rats following surgical transection, with histological assessment showing improved collagen fiber organization and increased tendon tensile strength in treated versus saline-control animals. Pevec et al. (Journal of Orthopaedic Surgery and Research, 2010) reported comparable improvements in a medial collateral ligament transection model. A 2026 review in the International Journal of Molecular Sciences (DOI: 10.3390/ijms27062876) summarized the current tendon and ligament data as "consistent across independent rodent models" while noting that human replication data is absent.

Muscle

Studies in rat gastrocnemius crush injury models have reported reduced necrotic area and earlier return of fiber organization in BPC-157-treated animals compared to controls, with the proposed mechanism involving VEGF-driven revascularization of the damaged tissue (Novinscak et al., Annals of the New York Academy of Sciences, 2008).

Bone

Augustin et al. (2014, Journal of Orthopaedic Research) examined BPC-157 in a rat segmental bone defect model, reporting improvements in densitometric and histomorphometric healing parameters in treated animals. The authors proposed enhanced osteoblast recruitment and periosteal vascularization as contributing mechanisms.

Gastrointestinal Tract

BPC-157's earliest preclinical characterization was as a gastroprotective agent. Studies in NSAID-induced gastric ulceration models in rats (Sikiric et al., Journal of Physiology — Paris, 1997) reported significant reductions in lesion area and improved mucosal integrity. The compound was subsequently tested in models of inflammatory bowel disease (TNBS-induced colitis; Veljaca et al., 1994), short bowel syndrome, and anastomotic healing, consistently showing improvements in tissue integrity endpoints versus control animals (Drmic et al., World Journal of Gastroenterology, 2018).

Peripheral Nerve

A 2022 study published in Biomedicines examined BPC-157 in a rat sciatic nerve crush model, reporting accelerated functional recovery and improved histological nerve fiber organization in treated animals compared to controls — an extension of the tissue-repair data into peripheral neurological contexts.

Pain Modulation Research

The March 2026 International Journal of Molecular Sciences review (DOI: 10.3390/ijms27062876) dedicated a section to BPC-157's effects in preclinical pain models, noting that studies in rodent models of nociception — including inflammatory, neuropathic, and visceral pain paradigms — have reported analgesic-like effects. Proposed mechanisms include peripheral anti-inflammatory cytokine modulation and nitric oxide-mediated vasodilation in injured tissue. This analgesia data represents an emerging area of investigation distinct from the classical tissue-repair literature.

Safety and Toxicology Data

Long-term rodent studies extending across multiple months have generally reported favorable tolerability profiles for BPC-157, with no carcinogenic outcomes identified in the reviewed literature. However, two important caveats apply:

Single-group concentration of data. The overwhelming majority of primary research originates from the Sikiric laboratory at the University of Zagreb. Independent replication by unaffiliated groups is limited, and this represents a recognized gap in the evidence base.
Cancer safety debate. A February 2026 STAT News investigative report raised concerns about BPC-157's theoretical pro-proliferative potential, citing its VEGF-stimulating and EGR-1 activating properties as mechanistically consistent with tumor-promoting activity in contexts of pre-existing malignancy. The published animal studies did not include oncology-focused safety endpoints as primary endpoints, leaving this question open. Researchers working in oncology contexts have noted the theoretical concern; no published study has demonstrated tumor-promoting activity directly attributable to BPC-157 under controlled conditions.

Regulatory Status (Updated June 2026)

BPC-157 does not hold FDA approval, EMA approval, or comparable regulatory clearance for any therapeutic indication in any jurisdiction.

503A/503B compounding status: BPC-157 was previously classified in the FDA's 503A Category 2 list (bulk drug substances with significant safety concerns that preclude compounding). In April 2026, the FDA removed BPC-157 from Category 2 following withdrawal of those concerns and scheduled a formal Pharmacy Compounding Advisory Committee (PCAC) review.

July 23, 2026 PCAC Meeting: The FDA's PCAC is scheduled to evaluate BPC-157 free base and BPC-157 acetate as two separate nominations for the 503A Bulk Drug Substances positive list. The committee will review available preclinical data, toxicology, and historical use evidence, and vote on whether to recommend each form for addition to the compounding-permitted list. A positive PCAC recommendation is non-binding and would still require subsequent FDA rulemaking — a process that typically takes a year or more — before licensed compounding pharmacies could lawfully produce the compound.

Researchers interested in updated regulatory status should consult the BPC-157 compound library entry and monitor the FDA advisory committee calendar.

Key Publications

Sikiric, P. et al. (1993). "The influence of a novel pentadecapeptide, BPC 157, on NO-system and stomach mucosa integrity." European Journal of Pharmacology. PMID: 8281067
Chang, C.H. et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. PMID: 21979810
Sikiric, P. et al. (2018). "Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications." Current Neuropharmacology. PMID: 29308739
Drmic, D. et al. (2018). "Counteraction of surgically and non-surgically induced fistulas by BPC 157 in rats." World Journal of Gastroenterology. PMID: 29434470
Pevec, D. et al. (2010). "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor. PMID: 20110913
Review (2026). "From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management." International Journal of Molecular Sciences. DOI: 10.3390/ijms27062876

Research Limitations

Despite a substantial volume of preclinical data accumulated over three decades, BPC-157 has not completed Phase 2 or Phase 3 human clinical trials for any indication. The evidence base has the following structural limitations:

Source concentration: The majority of primary publications originate from a single research group, which limits independent verification.
Species translation: All therapeutic findings are from rodent models. Translation to human pharmacology, dosing, and safety has not been established.
Formulation variability: Published studies use varying administration routes (oral, intraperitoneal, subcutaneous), doses, and formulations, making cross-study quantitative comparison difficult.
Mechanistic gaps: Proposed mechanisms (EGR-1 upregulation, NO system cross-talk) are based on indirect evidence and have not been validated in human cell systems with the same rigor applied in clinical pharmacology.

Researchers should consult the primary literature and the BPC-157 compound library entry for the most current data and regulatory updates.

All content on ClinicalPeptide.org is intended for researchers and educators working in biochemistry, pharmacology, and related disciplines. Nothing on this site constitutes medical advice, and no information should be interpreted as guidance for human self-administration of any compound.